Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of Vericheck ddPCR™ Empty-Full Capsid Kits for adeno-associated virus (AAV) serotypes 2 and 8, enabling determination of capsid titer, genome titer, and percentage of full capsids in purified or unpurified (crude lysate) samples.


Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Together with the existing Vericheck ddPCR Empty-Full Capsid Kits for serotypes AAV5 and AAV9, the addition of the new kits for serotypes AAV2 and AAV8 extends the range’s suitability to approximately 70% of the AAV gene therapy market, with AAV2 being the most prevalent serotype in clinical trials. Each AAV serotype exhibits unique properties that influence tissue tropism and therapeutic goal, allowing tailored approaches for gene therapy applications.

With the absolute quantification provided by Bio-Rad’s Droplet Digital™ PCR, the Vericheck ddPCR Empty-Full Capsid Kits require minimal volumes of either crude lysate or purified samples to deliver robust, reproducible data for reliable assessment for critical quality attributes (CQAs) in AAV vector production. Designed and validated for Bio-Rad’s Droplet Digital PCR Systems, the kits provide consistent capsid content measurements across the AAV production process in line with regulatory guidelines, streamlining gene therapy development. Bio-Rad delivers a comprehensive solution for AAV vector characterization, driving the development of safe and effective gene therapies.

“AAVs are widely regarded as one of the most effective vectors for gene therapy, thanks to their ability to transduce a diverse range of mammalian cell types and to their nonpathogenic nature,” said Steve Kulisch, Vice President Product Management, Digital Biology Group, Bio-Rad Laboratories. “Our portfolio of Vericheck ddPCR Empty-Full Capsid Kits facilitates the advancement of gene therapies, employing the four most common AAV serotypes used in clinical trials today. By providing customers with a cost-effective and accessible solution for a wider choice of serotypes, the kits support tailored approaches to gene therapy development, delivering unmatched precision and specificity for AAV vector characterization processes.”

Share
You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio